Actively Recruiting
LOCATOR - Locally Optimised Contouring With AI Technology for Radiotherapy
Led by Royal North Shore Hospital · Updated on 2026-01-29
444
Participants Needed
3
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates the use of artificial intelligence (AI) to assist in contouring during radiation treatment for breast cancer patients. The trial compares AI-assisted contouring using the in-house LOCATOR software with fully manual contouring done by radiation oncologists. The study aims to evaluate whether AI-assisted contouring matches the quality of manual contouring and whether it can save oncologists time. It is a multicenter, phase II randomized controlled trial focusing on contour quality and efficiency. Participants are randomly assigned in a 3:1 ratio to either AI-assisted contouring or manual contouring groups. The AI model is initially trained on data from previous breast cancer cases and is updated regularly as more patients participate. In the AI-assisted group, contours are generated by the LOCATOR software and then manually reviewed and adjusted by oncologists. The manual group receives the standard care with contours created entirely by oncologists. During the study, researchers assess contour quality using the MD Anderson Contouring Grade Scale and various geometric and dosimetric measures. They also evaluate time savings, clinician-reported toxicity, patient-reported quality of life, and economic costs. Follow-up includes acute and late toxicity and quality of life assessments over 18 months to 5 years. Participant involvement includes contouring procedures, toxicity monitoring, questionnaires, and outcome evaluations over the study period.
CONDITIONS
Brief Title
Locally Optimised Contouring With AI Technology for Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years and older who are planned for primary breast malignancy
- ECOG performance status between 0 and 2
- Ability to understand and willingness to sign a written informed consent document
- Target volume must be reviewable by current national or international clinical guidelines
You will not qualify if you...
- Patients under 18 years of age
- Patients unable to understand consent documents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants receive contouring for radiotherapy either with AI-assisted software followed by manual edits or fully manual contouring by a radiation oncologist.
Visits scheduled as part of radiotherapy planning and treatment
Duration - Up to 5 years
Participants are monitored for acute and late toxicity, quality of life, and accuracy of contouring over time after treatment.
Periodic follow-up visits to assess health outcomes and quality of life
Trial Site Locations
Total: 3 locations
1
Western Cancer Centre Dubbo
Dubbo, New South Wales, Australia, 2830
Actively Recruiting
2
Central West Cancer Centre
Orange, New South Wales, Australia, 2800
Actively Recruiting
3
Department of Radiation Oncology, Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
Actively Recruiting
Research Team
J
Joseph Chan, BSc MBBS PhD FRANZCR
H
Heidi Tsang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here